カテゴリー： Transparency Market Research, 世界, 医療/バイオ

HER2検査の世界市場2023～2031：技術別

◆英語タイトル：HER2 Testing Market [Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization (CISH) & Silver-enhanced in situ hybridization] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが発行した調査報告書（TMR23JUL223）◆商品コード：TMR23JUL223
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2023年5月
◆ページ数：176
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社が発表した市場調査レポートによると、世界のHER2検査市場規模は2023年135.2百万ドルから予想期間中、年平均7.3％成長し、2031年までに259.4百万ドルへ到達すると見込まれています。当レポートでは、HER2検査の世界市場を対象に、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、技術別（FISH法、二重プローブ、単一プローブ、発色in situハイブリダイゼーション（CISH）法、銀強化in situハイブリダイゼーション）分析、がん種類別（乳がん、胃がん）分析、エンドユーザー別（病院、診断研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を調査し、まとめています。なお、こちらのレポートに記載されている企業情報は、Abbott、Hoffmann-La Roche Ltd、Agilent Technologies, Inc.、Thermo Fisher Scientific, Inc.、Leica Biosystems (Danaher Corporation)、Empire Genomics, Inc. (Biocare Medical, LLC)、Bio-Genex Laboratories、Abnova Corporationなどが包含されています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要洞察
・世界のHER2検査市場規模：技術別
- FISH法における市場規模
- 二重プローブにおける市場規模
- 単一プローブにおける市場規模
- 発色in situハイブリダイゼーション（CISH）法における市場規模
- 銀強化in situハイブリダイゼーション法における市場規模
・世界のHER2検査市場規模：がん種類別
- 乳がんにおける市場規模
- 胃がんにおける市場規模
・世界のHER2検査市場規模：エンドユーザー別
- 病院における市場規模
- 診断研究所における市場規模
- その他エンドユーザーにおける市場規模
・世界のHER2検査市場規模：地域別
- 北米のHER2検査市場規模
- ヨーロッパのHER2検査市場規模
- アジア太平洋のHER2検査市場規模
- 中南米のHER2検査市場規模
- 中東・アフリカのHER2検査市場規模
・競争状況

HER2 Testing Market – Scope of Report
TMR’s report on the global HER2 Testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global HER2 Testing market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HER2 Testing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the HER2 Testing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HER2 Testing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HER2 Testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HER2 Testing market.

The report delves into the competitive landscape of the global HER2 Testing market. Key players operating in the global HER2 Testing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HER2 Testing market profiled in this report.

Key Questions Answered in Global HER2 Testing Market Report
• What is the sales/revenue generated by HER2 Testing across all regions during the forecast period?
• What are the opportunities in the global HER2 Testing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

HER2 Testing Market – Research Objectives and Research Approach
The comprehensive report on the global HER2 Testing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global HER2 Testing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HER2 Testing market.

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global HER2 Testing Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global HER2 Testing Market Analysis and Forecasts, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Detailed Analysis of HER2 Expression in Gastric & Gastroesophageal Cancer
    5.2. Breast and Gastric Cancer Prevalence & Incidence Rate globally with key countries
    5.3. Regulatory Scenario
    5.4. Key Industry Developments
    5.5. Pipeline Analysis for Gastric Cancer
    5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact)
6. Global HER2 Testing Market Analysis and Forecast, by Technique
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Technique, 2017-2031
        6.3.1. Fluorescence in situ hybridization
        6.3.2. Dual-probe
        6.3.3. Single-probe
        6.3.4. Chromogenic in situ hybridization (CISH)
        6.3.5. Silver-enhanced in situ hybridization
    6.4. Market Attractiveness, by Technique
7. Global HER2 Testing Market Analysis and Forecast, by Cancer Type
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Cancer Type, 2017-2031
        7.3.1. Breast Cancer
        7.3.2. Gastric Cancer
    7.4. Market Attractiveness, by Cancer Type
8. Global HER2 Testing Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by End-user, 2017-2031
        8.3.1. Hospitals
        8.3.2. Diagnostic Laboratories
        8.3.3. Others
    8.4. Market Attractiveness, by End-user
9. Global HER2 Testing Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness, by Country/Region
10. North America HER2 Testing Market  Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Technique, 2017-2031
        10.2.1. Fluorescence in situ hybridization
        10.2.2. Dual-probe
        10.2.3. Single-probe
        10.2.4. Chromogenic in situ hybridization (CISH)
        10.2.5. Silver-enhanced in situ hybridization
    10.3. Market Value Forecast, by Cancer Type, 2017-2031
        10.3.1. Breast Cancer
        10.3.2. Gastric Cancer
    10.4. Market Value Forecast, by End-user, 2017-2031
        10.4.1. Hospitals
        10.4.2. Diagnostic Laboratories
        10.4.3. Others
    10.5. Market Value Forecast, by Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Technique
        10.6.2. By Cancer Type
        10.6.3. By End-user
        10.6.4. By Country
11. Europe HER2 Testing Market  Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Technique, 2017-2031
        11.2.1. Fluorescence in situ hybridization
        11.2.2. Dual-probe
        11.2.3. Single-probe
        11.2.4. Chromogenic in situ hybridization (CISH)
        11.2.5. Silver-enhanced in situ hybridization
    11.3. Market Value Forecast, by Cancer Type, 2017-2031
        11.3.1. Breast Cancer
        11.3.2. Gastric Cancer
    11.4. Market Value Forecast, by End-user, 2017-2031
        11.4.1. Hospitals
        11.4.2. Diagnostic Laboratories
        11.4.3. Others
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Technique
        11.6.2. By Cancer Type
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific HER2 Testing Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Technique, 2017-2031
        12.2.1. Fluorescence in situ hybridization
        12.2.2. Dual-probe
        12.2.3. Single-probe
        12.2.4. Chromogenic in situ hybridization (CISH)
        12.2.5. Silver-enhanced in situ hybridization
    12.3. Market Value Forecast, by Cancer Type, 2017-2031
        12.3.1. Breast Cancer
        12.3.2. Gastric Cancer
    12.4. Market Value Forecast, by End-user, 2017-2031
        12.4.1. Hospitals
        12.4.2. Diagnostic Laboratories
        12.4.3. Others
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Technique
        12.6.2. By Cancer Type
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America HER2 Testing Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Technique, 2017-2031
        13.2.1. Fluorescence in situ hybridization
        13.2.2. Dual-probe
        13.2.3. Single-probe
        13.2.4. Chromogenic in situ hybridization (CISH)
        13.2.5. Silver-enhanced in situ hybridization
    13.3. Market Value Forecast, by Cancer Type, 2017-2031
        13.3.1. Breast Cancer
        13.3.2. Gastric Cancer
    13.4. Market Value Forecast, by End-user, 2017-2031
        13.4.1. Hospitals
        13.4.2. Diagnostic Laboratories
        13.4.3. Others
    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Technique
        13.6.2. By Cancer Type
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa HER2 Testing Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Technique, 2017-2031
        14.2.1. Fluorescence in situ hybridization
        14.2.2. Dual-probe
        14.2.3. Single-probe
        14.2.4. Chromogenic in situ hybridization (CISH)
        14.2.5. Silver-enhanced in situ hybridization
    14.3. Market Value Forecast, by Cancer Type, 2017-2031
        14.3.1. Breast Cancer
        14.3.2. Gastric Cancer
    14.4. Market Value Forecast, by End-user, 2017-2031
        14.4.1. Hospitals
        14.4.2. Diagnostic Laboratories
        14.4.3. Others
    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Technique
        14.6.2. By Cancer Type
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of companies)
    15.2. Market Share Analysis By Company (2022)
    15.3. Company Profiles
        15.3.1. Abbott
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Strategic Overview
        15.3.2. Hoffmann-La Roche Ltd
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Strategic Overview
        15.3.3. Agilent Technologies, Inc.
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Strategic Overview
        15.3.4. Thermo Fisher Scientific, Inc.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Strategic Overview
        15.3.5. Leica Biosystems (Danaher Corporation)
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Strategic Overview
        15.3.6. Empire Genomics, Inc. (Biocare Medical, LLC)
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Strategic Overview
        15.3.7. Bio-Genex Laboratories
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Strategic Overview
        15.3.8. Abnova Corporation
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Strategic Overview
        15.3.9. Oxford Gene Technology IP Limited (Sysmex Corporation)
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Strategic Overview

List of Tables

Table 01: Global HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031

Table 02: Global HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031

Table 03: Global HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031

Table 04: Global HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 05: Global HER2 Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 06: North America HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 07: North America HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031

Table 08: North America HER2 Testing Market size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031

Table 09: North America HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031

Table 10: North America HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 11: Europe HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 12: Europe HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031

Table 13: Europe HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031

Table 14: Europe HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031

Table 15: Europe HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 16: Asia-Pacific HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 17: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031

Table 18: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031

Table 19: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031

Table 20: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 21: Latin America HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 22: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031

Table 23: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031

Table 24: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031

Table 25: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 26: Middle East & Africa HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 27: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031

Table 28: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031

Table 29: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031

Table 30: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ HER2検査の世界市場2023～2031：技術別(HER2 Testing Market [Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization (CISH) & Silver-enhanced in situ hybridization] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • がんプロファイリングの世界市場2023～2031：製品別、がん種類別
  • 近接照射療法シードの世界市場2023～2031：放射性シード種類別、用途別

    • ◆H&Iグローバルリサーチのお客様（例）◆